Pharmafile Logo

News and Press Releases

ProteoNic 2G UNic Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

11 December 2025 -- Leiden, The Netherlands -- ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology...

Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 11, 2025

ProteoNic Biosciences
info@proteonic.nl
J.H. Oortweg 19-21 – 2333 CH Leiden – The Netherlands

Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for commercial production of drug substance

IBP-9414 targets mortality and gastrointestinal injury in premature infants With Breakthrough Therapy designation for gastro-intestinal mortality and Rare Paediatric Disease designations, IBP-9414 is on an accelerated path to commercialisation   PPQ...

Category: BioManufacturing, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: December 1, 2025

Recipharm

Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support

Telomir-1 has now entered GMP preparation, and Ketamir-2 has completed the Phase 1 SAD stage, reflecting steady advancement of both programmes These milestones mark tangible progress in development and demonstrate...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 26, 2025

Recipharm

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Immune response successfully improved with second generation vaccine candidate4 November 2025 -- Saint-Herblain, France -- Valneva SE, a specialty vaccine company, today announced positive results of its Phase 1 clinical...

Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: November 4, 2025

Valneva
communications@valneva.com
6 rue Alain Bombard, 44800 Saint-Herblain, France

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression to phase 2 clinical trials in Malawi Demonstrates Recipharm’s agility and flexibility, completing full tech transfer, scale-up and process optimisation within three...

Category: BioManufacturing, Drug Delivery, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 15, 2025

Evonik and Ethris enter strategic partnership to expand offerings for nucleic acid delivery

Developing and manufacturing innovative LNP delivery technology for respiratory medicine and beyond Expanding Evonik’s CDMO offerings, enabling efficient translation from concept to clinic Accelerating RNA-based therapeutic solutions for customers through...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 9, 2025

Ethris
https://www.ethris.com/

Terumo BCT and PwC Belgium Join Forces to Break Barriers in Access to Advanced Cell and Gene Therapies 

2 September 2025 -- Brussels, Belgium -- Terumo Blood and Cell Technologies, (Terumo BCT), a medical technology company, and PwC Belgium today announce a new collaboration focused on driving equitable...

Category: Biotechnology, Drug Discovery, Logistics, Manufacturing and Packing
Posted: September 8, 2025

Terumo Blood and Cell Technologies
Old Belfast Road Millbrook Larne BT40 2SH

Upperton Pharma Solutions Advancing Oral Vaccines Delivery with Oxford’s Pandemic Sciences Institute

14 August 2025 -- Nottingham, UK -- Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), has been awarded a grant as part of the first VaxHub Sustainable Platform Funding...

Category: Biotechnology, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: August 14, 2025

Upperton Pharma Solutions
contact@upperton.com
Albert Einstein Centre, Nottingham Science Park, Nottingham, UK, NG7 2TN

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. 10 June...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: June 10, 2025

Innoviva
info@istx.com
Boston BioHub 35 Gatehouse Drive Waltham, MA USA 02451

University of Oxford and ReciBioPharm expand strategic collaboration in fight against malaria

Expands the collaboration to manufacture two malaria vaccine candidates (R78C and RH5.1) for Phase 1/2 clinical trials Delivers the sixth malaria vaccine candidate for the University of Oxford Provides drug...

Category: Biotechnology, Clinical Trials, Logistics, Manufacturing and Packing, Pharmaceutical
Posted: June 9, 2025

Recipharm

Liverpool City Region set to become global powerhouse in new front for fighting disease and driving wellbeing

23 April 2025 -- Liverpool, UK -- Liverpool City Region is set to become a global powerhouse in a new front to tackle deadly diseases and improve wellbeing. More than...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

The University of Liverpool
Foundation Building Brownlow Hill Liverpool L69 7ZX

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

23 April 2025 -- Ingelheim, Germany and Amsterdam, the Netherlands -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Boehringer Ingelheim
Binger Strasse 173 55216 Ingelheim am Rhein

US FDA Grants Qualified Infectious Disease Product Designation to Venus Remedies’ VRP-034, a Novel Polymyxin B Formulation

VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate, uniquely developed to mitigate the nephrotoxic effects associated with conventional polymyxin B (PMB) therapy Key preclinical findings for...

Category: Biotechnology, Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: April 17, 2025

Venus Remedies
info@venusremedies.com, bd@venusremedies.com
51-52, Industrial Area Phase-1, Panchkula, Haryana, 134113

Spektus Pharma and Recipharm Announce Strategic Partnership to Develop and Supply CNS Medicines Using Flexitab™ Oral Drug Delivery Platform

22 January 2025 -- Montreal, Canada -- Spektus Pharma, an innovator in value added medicine development, and Recipharm, a leading global contract development and manufacturing organization, have entered into a...

Category: Drug Discovery, Other, Pharmaceutical
Posted: January 22, 2025

Recipharm

Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration

Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties 7 January 2025 -- California, US -- Capsida Biotherapeutics today announced that AbbVie has...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025

Capsida Biotherapeutics
info@capsida.com
1300 Rancho Conejo Blvd. Thousand Oaks, CA 91320